Fitzsimons Innovation Community is an integrated urban campus where health and life sciences companies of all sizes work on their next big things. Our customized workspace, collaborative campus, and proximity to one of the top health systems and medical schools in the country make our community the perfect place to put down roots and get to work.
MOVE-IN READY LAB SPACE
GROWTH OPPORTUNITIES
It’s not just additional space—it’s fifty sprawling acres of additional space. And it’s primed for ultra-custom, made-to-order facility development.
Fitzsimons Innovation Community and University of Colorado Anschutz Medical Campus working together.
Relationships that help you thrive.
FEATURED:
One of the most exciting times of year for us here at Fitzsimons Innovation Community is when we launch our Annual Innovation Report, and this year is no different. For the fourth year in a row, we are proud to share this report featuring updates, insight, and data about all the things that make our Community special.
Fitzsimons Innovation Community is where innovators come to turn ideas into business.
A monthly feature of a Fitzsimons Innovation Community visionary.
Our year in innovation.
Find out what’s happening on campus and across the industry.
An urban mountain lifestyle for work and play.
Everything you need.
Right here.
Read Fitzsimons Innovation Community news, industry highlights, editorials, and innovation updates happening weekly on our campus.
Explore how Atara's investigational EBV T-cell platform-based therapies target cancer and autoimmune diseases are manufactured.
Rather than just redirecting flow, implantations provide therapy to heart cells and drive new tissue
Ceria Therapeutics, Inc. (Ceria), a Colorado-based biotech startup focusing on the development of novel therapeutics to address several inflammatory diseases, today announced the company has received a second Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). This award is directed to development of CTX-001 for the treatment of non-healing diabetic foot ulcers (DFUs).
University of Colorado faculty this year attracted $1.46 billion in sponsored research funding and gifts supporting research. The support powers wide-ranging discovery and impact, ultimately benefiting Colorado, the nation and the world.
Foresight Diagnostics, Inc, a leader in cancer diagnostics and cancer relapse testing, announced today that the U.S. Patent and Trademark Office (USPTO) has granted the company patent No. 11,447,833 for the detection of minimal residual disease (MRD) using its personalized phased variant detection platform. "We are pleased that the USPTO has recognized the novel nature of our proprietary technology and are excited about the impact we believe this technology will have on the lives of cancer patients," said Dr. Jake Chabon, Ph.D., Chief Executive Officer of Foresight Diagnostics.
"Ventria’s success in excluding unfairly traded imports secures its ability to continue to invest in the next generation of plant biotechnology innovation"
Atara Biotherapeutics and their partner Pierre Fabre Group announce that the European Medicines Agency's CHMP issued a positive opinion for their investigational therapy to treat adult and pediatric patients 2 years of age and older with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease.
Fitzsimons Innovation Community
